Evidence map›Paper›PMID 37021060›Full record

ArticleFrontiers in pharmacology2023

Leveraging

Elliot Offman, Noopur Singh, Mark W Julian, Landon W Locke, Sabahattin Bicer, Jonah Mitchell, Thomas Matthews, Kirsten Anderson, Elliott D Crouser

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. The Renin-Angiotensin-Aldosterone System Regulates Sarcoidosis Granulomatous Inflammation.American journal of respiratory and critical care medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Elliot OffmanCertara, Princeton, NJ, United States.
Noopur SinghXentria, Inc., Chicago, IL, United States.
Mark W JulianDivision of Pulmonary, Critical Care and Sleep Medicine, The Dorothy M. Davis Heart and Lung Research Institute, Columbus, OH, United States.
Landon W LockeDepartment of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Sabahattin BicerDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
Jonah MitchellDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
Thomas MatthewsXentria, Inc., Chicago, IL, United States.
Kirsten AndersonXentria, Inc., Chicago, IL, United States.
Elliott D CrouserDivision of Pulmonary, Critical Care and Sleep Medicine, The Dorothy M. Davis Heart and Lung Research Institute, Columbus, OH, United States.
The Ohio State University · USLung Institute · USIntegra LifeSciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

granulomapopulation pharmacokinetic modelingsarcoidosisTNFαXTMAB-16

Identifiers

PMID37021060
PMCPMC10067675
OpenAlexW4327979113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.